It's been a rotten year for Gilead Sciences (NASDAQ: GILD) shareholders. The biotech stock is down over 25% in 2016. Sales for hepatitis C virus (HCV) drugs Harvoni and Sovaldi are dropping like a brick. This sales trend appears likely to continue into the new year. Could 2017 be Gilead's worst year yet? Image source: Getty Images.
Posted: 2016-12-25 21:55:00